OncoMatch/Clinical Trials/NCT07033026

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Is NCT07033026 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including NGM120 Q4W and NGM120 Q8W for colorectal cancer.

Phase 2RecruitingNGM Biopharmaceuticals, IncNCT07033026Data as of May 2026

Treatment: NGM120 Q4W · NGM120 Q8W — A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

NGM Clinical Study Site · Laredo, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify